A group of 53 biotech leaders are expressing their support for mifepristone in a letter to the Food and Drug Administration, urging the agency not to impose new restrictions on its use as an abortion medication and slamming a “fatally
read moreChinese regulators have approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. More: China approves 4 new drugs, including a global first-in-class medicine Source: fierce
read moreAstraZeneca CEO Pascal Soriot is plotting a shift of the company’s primary stock listing from the London to the U.S., according to The Times. In the report, the British news outlet cites multiple unnamed sources, including one who added that
read moreIn this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth
read moreWhether it’s drug developers being pressured to wind down or investors accused of trying to “strip mine” a biopharma, shareholder meetings are increasingly becoming verbal battlegrounds for beleaguered biotechs. More: Why 'emboldened' activist investors are taking the fight to biotechs
read moreAfter taking aim at the United States’ vaccine safety reporting system earlier this year, Robert F. Kennedy Jr. has added a federal vaccine injury compensation program to his list of immunization bugbears. And this time around, the HHS Secretary says
read more© 1994 - 2025 B.M. Pharmaceuticals